Dr. Huttunen has a Ph.D. degree in biochemistry and has previously held research positions at the University of Helsinki, Massachusetts General Hospital, Harvard Medical School and Orion Pharma.
He is one of co-founders of Herantis Pharma Plc, listed in the NASDAQ Helsinki Stock Exchange First North marketplace, and has served as the Chief Scientific Officer since 2014. Previously, Dr. Huttunen lead a research group at the Neuroscience Center, University of Helsinki.
For more than 20 years, his research has focused on molecular mechanisms and development of novel therapies for neurodegenerative diseases, including Parkinson’s and Alzheimer’s diseases.
